A Multicenter, Prospective Study of a New Fully Covered Expandable Metal Biliary Stent for the Palliative Treatment of Malignant Bile Duct Obstruction

Charlton 8, GI Endoscopy, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
Gastroenterology Research and Practice (Impact Factor: 1.75). 03/2013; 2013:642428. DOI: 10.1155/2013/642428
Source: PubMed


Background and Study Aims. Endoscopic placement of self-expanding metal stents (SEMSs) is indicated for palliation of inoperable malignant biliary obstruction. A fully covered biliary SEMS (WallFlex Biliary RX Boston Scientific, Natick, USA) was assessed for palliation of extrahepatic malignant biliary obstruction. Patients and Methods. 58 patients were included in this prospective, multicenter series conducted under an FDA-approved IDE. Main outcome measurements included (1) absence of stent occlusion within six months or until death, whichever occurred first and (2) technical success, need for reintervention, bilirubin levels, stent patency, time to stent occlusion, and adverse events. Results. Technical success was achieved in 98% (57/58), with demonstrated acute removability in two patients. Adequate clinical palliation until completion of followup was achievedin 98% (54/55) of evaluable patients, with 1 reintervention due to stent obstruction after 142 days. Mean total bilirubin decreased from 8.9 mg/dL to 1.2 mg/dL at 1 month. Device-related adverse events were limited and included 2 cases of cholecystitis. One stent migrated following radiation therapy. Conclusions. The WallFlex Biliary fully covered stent yielded technically successful placement with uncomplicated acute removal where required, appropriate reduction in bilirubin levels, and low rates of stent migration and occlusion. This SEMS allows successful palliation of malignant extrahepatic biliary obstruction.

Download full-text


Available from: Michael Gluck
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biliary stenting has evolved dramatically since endoscopic placement of the first stent in 1980. Endoscopic stenting has largely supplanted surgical bypass for palliation of malignant biliary obstruction. Plastic stents were traditionally used due their low cost and removability, with albeit limited duration of patency. The development of self-expanding metal stents (SEMS) represents a major advance in the treatment of obstructive biliary disease, providing an increased luminal diameter and patency. Metallic biliary stenting, however, has significant limitations including mucosal hyperplasia occurring within the stent leading to in-stent restenosis, and lack of removability. The recent introduction of fully covered self-expanding metal stents (FCSEMS) has helped overcome some of these limitations. Randomized clinical trials using FCSEMS have shown a reduction in stent ingrowth and an increased ability to remove stents as compared with uncovered metal stents. In this article, we summarize recent developments in the design and applications of FCSEMS, and compare findings of recent clinical studies.
    No preview · Article · Nov 2013 · Practical gastroenterology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Covered metallic stents (CMSs) were developed to overcome tumor ingrowth in uncovered metallic stents (UMSs) for malignant biliary obstruction, but superiority of CMSs over UMSs is still controversial due to the high migration rate in CMS. Therefore, we conducted this retrospective analysis to clarify risk factors for stent migration including mechanical properties of CMSs.Methods Patients with unresectable pancreatic cancer, receiving CMS for distal malignant biliary obstruction in 5 tertiary care centers, were retrospectively studied. Univariate and multivariate analyses to identify prognostic factors for early (<6 months) stent migration were performed using a proportional hazards model with death or stent occlusion without stent migration as a competing risk. Two mechanical properties were included in the analysis: axial force (AF), the recovery force that leads to a CMS straightening, and radial force (RF), the expansion force against the stricture.ResultsAmong 290 patients who received CMS placement for distal malignant biliary obstruction, stent migration rate was 15.2%. CMS migrated early (<6 months) in 10.0% and distally in 11.7%, respectively. In the multivariate analysis, significant risk factors for early stent migration were chemotherapy (subdistribution hazard ratios [SHR] 4.46, p = 0.01), CMS with low RF (SHR 2.23, p = 0.03) and duodenal invasion (SHR 2.25, p = 0.02).ConclusionCMS with low RF, chemotherapy and duodenal invasion were associated with CMS migration from our study.
    No preview · Article · Apr 2014 · Journal of Gastroenterology and Hepatology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endoscopic insertion of a self-expanding metal stent (SEMS) through a malignant common bile duct stricture is the first line of palliation for malignant jaundice. Patency of these stents remains a major concern. SEMS dysfunction can result from tumor ingrowth, overgrowth and/or clogging. Initial SEMS modifications involved covering the central part of the stent in order to reduce ingrowth and ultimately increase patency. Fully covered stents became available shortly after reports of their use in human patients. The potential removability and radial strength of SEMS have led to evaluation of their use in new indications including benign biliary strictures, post sphincterotomy bleeding and perforation. Other aspects of development include the addition of features such as anti-reflux valves, drug elution and spontaneous biodegradability. These aspects and their clinical implications are reviewed and discussed.
    No preview · Article · Sep 2014 · Expert Review of Gastroenterology and Hepatology